Clinical Trials Logo

Recurrent Extrahepatic Bile Duct Carcinoma clinical trials

View clinical trials related to Recurrent Extrahepatic Bile Duct Carcinoma.

Filter by:
  • None
  • Page 1

NCT ID: NCT02042443 Active, not recruiting - Clinical trials for Advanced Adult Hepatocellular Carcinoma

Trametinib or Combination Chemotherapy in Treating Patients With Refractory or Advanced Biliary or Gallbladder Cancer or That Cannot Be Removed by Surgery

Start date: February 2014
Phase: Phase 2
Study type: Interventional

This randomized phase II trial studies how well trametinib or combination chemotherapy works in treating patients with refractory or advanced biliary or gallbladder cancer or that cannot be removed by surgery. Trametinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as fluorouracil, leucovorin calcium, and capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether giving trametinib is more effective than combination chemotherapy in treating patients with biliary or gallbladder cancer.

NCT ID: NCT01093222 Completed - Clinical trials for Hilar Cholangiocarcinoma

Sorafenib Tosylate and Erlotinib Hydrochloride in Treating Patients With Locally Advanced, Unresectable, or Metastatic Gallbladder Cancer or Cholangiocarcinoma

Start date: April 2010
Phase: Phase 2
Study type: Interventional

This phase II trial is studying how well giving sorafenib tosylate together with erlotinib hydrochloride works in treating patients with locally advanced, unresectable, or metastatic gallbladder cancer or cholangiocarcinoma. Sorafenib tosylate and erlotinib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth or by blocking blood flow to the tumor.